share_log

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

Aurora Cannabis | 6-K: Report of foreign private issuer (related to financial reporting)

極光大麻 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/08/07 19:21

Moomoo AI 已提取核心訊息

Aurora Cannabis delivered strong Q1 FY2025 results with total net revenue increasing 12% YoY to $83.4M, driven by record medical cannabis revenue of $47.2M. The company achieved positive free cash flow of $6.5M and adjusted EBITDA of $4.9M, up 87% YoY. Medical cannabis segment contributed 57% of total revenue with a 69% adjusted gross margin.The company's plant propagation business Bevo grew 16% YoY to $23.1M in revenue, while consumer cannabis revenue declined 10% to $11.5M due to prioritizing higher-margin international medical sales. Aurora maintained a strong balance sheet with $182M cash position and became debt-free in its cannabis business, excluding Bevo's non-recourse debt.Looking ahead to Q2 FY2025, Aurora expects continued strong revenue and margins in its cannabis business, supported by growth in Europe and Australia. While positive adjusted EBITDA is expected to continue, free cash flow may be impacted by significant annual and one-time payments typically occurring in Q2.
Aurora Cannabis delivered strong Q1 FY2025 results with total net revenue increasing 12% YoY to $83.4M, driven by record medical cannabis revenue of $47.2M. The company achieved positive free cash flow of $6.5M and adjusted EBITDA of $4.9M, up 87% YoY. Medical cannabis segment contributed 57% of total revenue with a 69% adjusted gross margin.The company's plant propagation business Bevo grew 16% YoY to $23.1M in revenue, while consumer cannabis revenue declined 10% to $11.5M due to prioritizing higher-margin international medical sales. Aurora maintained a strong balance sheet with $182M cash position and became debt-free in its cannabis business, excluding Bevo's non-recourse debt.Looking ahead to Q2 FY2025, Aurora expects continued strong revenue and margins in its cannabis business, supported by growth in Europe and Australia. While positive adjusted EBITDA is expected to continue, free cash flow may be impacted by significant annual and one-time payments typically occurring in Q2.
極光大麻在2025財年第一季度交出了強勁的業績，總淨營業收入同比增長12%，達到8340萬美元，主要受醫療大麻創紀錄的營業收入4720萬美元的推動。公司實現了650萬美元的正自由現金流和490萬美元的調整後EBITDA，同比增長87%。醫療大麻部門貢獻了57%的總營業收入，調整後的毛利率爲69%。公司的植物繁殖業務Bevo同比增長16%，營業收入達到2310萬美元，而消費大麻的營業收入由於優先考慮更高毛利的國際醫療銷售而下降了10%，降至1150萬美元。極光保持了強勁的資產負債表，現金頭寸達到18200萬美元，並在其大麻業務中實現了無債務，排除Bevo的無追索權債務。展望2025財年第二季度，極光預計其大麻業務的營業收入和毛利將繼續強勁增長，得益於在歐洲和澳洲的增長。儘管預計調整後的EBITDA將繼續保持正值，但自由現金流可能會受到通常發生在第二季度的重大年度和一次性支付的影響。
極光大麻在2025財年第一季度交出了強勁的業績，總淨營業收入同比增長12%，達到8340萬美元，主要受醫療大麻創紀錄的營業收入4720萬美元的推動。公司實現了650萬美元的正自由現金流和490萬美元的調整後EBITDA，同比增長87%。醫療大麻部門貢獻了57%的總營業收入，調整後的毛利率爲69%。公司的植物繁殖業務Bevo同比增長16%，營業收入達到2310萬美元，而消費大麻的營業收入由於優先考慮更高毛利的國際醫療銷售而下降了10%，降至1150萬美元。極光保持了強勁的資產負債表，現金頭寸達到18200萬美元，並在其大麻業務中實現了無債務，排除Bevo的無追索權債務。展望2025財年第二季度，極光預計其大麻業務的營業收入和毛利將繼續強勁增長，得益於在歐洲和澳洲的增長。儘管預計調整後的EBITDA將繼續保持正值，但自由現金流可能會受到通常發生在第二季度的重大年度和一次性支付的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Citius Oncology
    CTOR
    -- 0.930
    腦再生科技
    RGC
    -- 31.880
    正業生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood醫藥
    IRWD
    -- 1.470
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點